Expert opinion on investigational drugs · 2008
Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yuan Zhe, Tam Vincent H
Аннотация
BACKGROUND: There has been a renewed interest in using polymyxin B as a last resort therapeutic option, due to emergence of multidrug-resistant Gram-negative bacteria. Despite being available for clinical use for decades, there is still a very limited understanding on many aspects of this agent.
OBJECTIVE: To review what is known about polymyxin B and to identify missing information or gaps for future investigations.
METHODS: Pertinent information was reviewed from published literature in English.
RESULTS/CONCLUSION: For optimal use of polymyxin B, a more thorough understanding is needed on standardized susceptibility testing, serum and tissue concentrations achieved, antibacterial activity when polymyxin B is combined with other agents, and mechanisms of resistance. A more precise characterization of the relationship between drug concentration and toxicity is also required.
OBJECTIVE: To review what is known about polymyxin B and to identify missing information or gaps for future investigations.
METHODS: Pertinent information was reviewed from published literature in English.
RESULTS/CONCLUSION: For optimal use of polymyxin B, a more thorough understanding is needed on standardized susceptibility testing, serum and tissue concentrations achieved, antibacterial activity when polymyxin B is combined with other agents, and mechanisms of resistance. A more precise characterization of the relationship between drug concentration and toxicity is also required.